疫苗预激活与CpG修饰T细胞疗法相结合,可促进免疫原性细胞死亡,并为肿瘤免疫疗法建立免疫记忆机制。
Combination of vaccine-primed and CpG-modified T cell therapy drives immunogenic cell death and immunological memory for tumor immunotherapy
Ruyi Wang, Xinyue Zhang, Han Yan, Jun Liu, Fengze Miao, Jiaye Lu, Zhen Cui, Zhongjian Chen, Zongguang Tai, Quangang Zhu
Journal:CHEMICAL ENGINEERING JOURNAL
IF:12.5
DOI:10.1016/j.cej.2026.181636
PMID:
Published:2026-09-06
research field:肿瘤学分子生物学肿瘤免疫学免疫治疗介入放射学
Abstract
rGBVac, a whole antigen cancer vaccine, robustly primes tumor-specific CD8 + T cells for synergistic therapy. • CpG@VT conjugated CpG on VT to get dual antitumor mechanisms that combine cytolysis with immunogenic cell death. • The sequential treatment strategy achieves immune amplification and sustains durable antitumor responses. While cell-based therapies have revolutionized cancer treatment, the efficacy of monotherapies against solid tumors remains limited by single-antigen targeting and poor persistence. Combining cancer vaccines with adoptive cell therapy represents a promising strategy to overcome these limitations through complementary mechanisms. Here, we developed a sequential strategy employing a whole-antigen nanovesicle vaccine (rGBVac) for initial immune priming. Subsequently, rGBVac-primed CD8 + T cells, surface-modified with the immune adjuvant CpG (CpG@VT), were adoptively transferred to achieve cross-stage immune stimulation. Mechanistically, CpG@VT mediated immediate cytotoxic elimination of tumor cells and induced immunogenic cell death, which triggered the secondary expansion of tumor-infiltrating dendritic cells and central memory T cells. Consequently, this “vaccine priming followed by adoptive cell transfer” strategy established durable immune memory and synergistically enhanced antitumor immunity. Collectively, this study presents a novel sequential treatment design of multidimensional synergistic immune amplification strategies.
本文使用的Yeasen产品
南美超级胎牛血清999尝鲜特惠


